- Home
- CAAP vs GERN Comparison
CAAP vs GERN Comparison
Compare CAAP & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAAP
- GERN
- Stock Information
- Founded
- CAAP 1998
- GERN 1990
- Country
- CAAP Luxembourg
- GERN United States
- Employees
- CAAP N/A
- GERN N/A
- Industry
- CAAP Aerospace
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- CAAP Consumer Discretionary
- GERN Health Care
- Exchange
- CAAP Nasdaq
- GERN Nasdaq
- Market Cap
- CAAP 2.4B
- GERN 2.5B
- IPO Year
- CAAP 2018
- GERN 1996
- Fundamental
- Price
- CAAP $19.00
- GERN $4.23
- Analyst Decision
- CAAP Strong Buy
- GERN Strong Buy
- Analyst Count
- CAAP 1
- GERN 9
- Target Price
- CAAP $21.50
- GERN $6.83
- AVG Volume (30 Days)
- CAAP 88.3K
- GERN 6.9M
- Earning Date
- CAAP 11-13-2024
- GERN 11-07-2024
- Dividend Yield
- CAAP N/A
- GERN N/A
- EPS Growth
- CAAP 114.63
- GERN N/A
- EPS
- CAAP 2.22
- GERN N/A
- Revenue
- CAAP $1,471,077,000.00
- GERN $1,373,000.00
- Revenue This Year
- CAAP $25.78
- GERN $23,693.67
- Revenue Next Year
- CAAP $18.74
- GERN $401.91
- P/E Ratio
- CAAP $8.53
- GERN N/A
- Revenue Growth
- CAAP N/A
- GERN 205.11
- 52 Week Low
- CAAP $10.57
- GERN $1.64
- 52 Week High
- CAAP $19.31
- GERN $5.34
- Technical
- Relative Strength Index (RSI)
- CAAP 60.61
- GERN 50.02
- Support Level
- CAAP $17.43
- GERN $3.88
- Resistance Level
- CAAP $19.22
- GERN $4.28
- Average True Range (ATR)
- CAAP 0.44
- GERN 0.16
- MACD
- CAAP 0.01
- GERN 0.02
- Stochastic Oscillator
- CAAP 72.24
- GERN 76.60
About CAAP Corporacion America Airports SA
Corporacion America Airports SA acquires, develops and operates airport concessions. Its operating segments are geographically divided into Argentina, Italy, Brazil, Uruguay, Ecuador and Armenia. The company generates a majority of its revenue from the Argentina segment. The firm's revenue is categorized into Aeronautical Revenue, Non-Aeronautical Revenue, Commercial Revenue, Construction Service Revenue, and Other Revenue.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.